Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family

Sullivan, Millicent M.; Sage, E. Helene

doi:10.1016/j.biocel.2004.01.017

Cited by 91 publications

(81 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This gene was first isolated by the screening of a rat brain expression library against synaptic junction glycoproteins of the central nervous system. Afterward, it was isolated from a human endothelial venule (HEV) cDNA library based on the differential screening of HEV and other vessels (13).…”

Section: Discussionmentioning

confidence: 99%

“…SPARCL1 has been found downregulated in many types of cancer, and has therefore been taken as a negative regulator of cell growth and proliferation (13,14). However, in situ hybridization has demonstrated the high expression of SPARCL1 in angiogenic endothelial cells in the stromal areas of invasive pancreatic adenocarcinoma (15).…”

Section: Discussionmentioning

confidence: 99%

“…SPARCL1 protein has a cysteine-rich region which exhibits a high affinity for copper ions (Cu 2+ ). Regions to which Cu 2+ binds have in particular been shown to regulate cell proliferation and angiogenesis (13). SPARC protein has been described as a target for cleavage by matrix metalloproteinases (MMPs).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

SPARC-like1 mRNA is overexpressed in human uterine leiomyoma

Mencalha

Levinsphul²,

Deterling³

et al. 2008

Mol Med Report

View full text Add to dashboard Cite

Abstract. Uterine leiomyomas (ULs), also known as fibroids, are benign and monoclonal tumors frequently found in the female population. The genetic alterations that contribute to UL tumor development have not been well established, and the goal of this study was to reveal gene expression variation between ULs and healthy uterine tissue. We compared the gene expression profiles of 13 UL tumors with that of their adjacent normal tissue using the Differential Display mRNA assay (DDRT-PCR). Among the genes upregulated in some of the UL samples, several genes previously described in the context of cancer were identified, namely LIMK1, MCM3 and UHRF1. In addition, we identified a cDNA present in UL samples from distinct patients, which was absent from their normal tissue. Direct sequencing of this cDNA revealed a human SPARC-like1 (SPARCL1) mRNA homology. Through semi-quantitative PCR, we demonstrated that SPARCL1 was upregulated in approximately 77% of UL samples, but was absent in normal tissue. Real-time PCR (QPCR) revealed that SPARCL1 expression was increased 5-fold in ULs compared to adjacent normal tissue. These results suggest that the SPARCL1 gene is involved in UL development.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SPARC-like1 mRNA is overexpressed in human uterine leiomyoma

Mencalha

Levinsphul²,

Deterling³

et al. 2008

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), also named as SC1, magnetassisted subtraction technique 9 (MAST9) or high endothelial venule protein (Hevin), is one of the ten members of SPARC-related family (Sullivan and Sage, 2004). SPARCL1 is localized to human chromosome 4q22-25 and its cDNA open reading frame includes 1992 nucleotides, encoding 664 amino acids (Isler et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Cao¹,

Kuo²,

Zhu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), an extracellular matrix glycoprotein, has been implicated in the pathogenesis of several disorders including cancer. However, little is known about the expression and significance of SPARCL1 in human breast cancer. The aim of this study was to determine the expression pattern and clinicopathological significance of SPARCL1 in a Chinese breast cancer cohort. mRNA and protein expression of SPARCL1 in human breast cancer cell lines and breast cancer tissues was detected using the reverse transcription-polymerase chain reaction, real-time quantitative PCR, and Western blotting, respectively. Immunostaining of SPARCL1 in 282 Chinese breast cancer samples was examined and associations with clinicopathological parameters were analyzed. Compared to the positive expression in immortalized human breast epithelial cells, SPARCL1 was nearly absent in human breast cancer cell lines. Similarly, a significantly reduced expression of SPARCL1 was observed in human breast cancer tissues compared to that in normal breast epithelial tissues, for both mRNA and protein levels (P < 0.001). Immunohistochemical analysis showed that strong cytoplasmic immunostaining of SPARCL1 was observed in almost all normal breast samples (43/45) while moderate and strong immunostaining of SPARCL1 was only detected in 191 of 282 (67.7%) breast cancer cases. Moreover, down-regulation of SPARCL1 was significantly correlated with lymphatic metastasis (P = 0.020) and poor grade (P = 0.044). In conclusion, SPARCL1 may be involved in the breast tumorigenesis and serve as a promising target for therapy of breast cancer.

show abstract

“…Therefore, SPARCL1 has been speculated as a tumor-associated endothelium marker associated with tumor 6 progression. Moreover, SPARCL1 has been proven as multifunctional glycoprotein, and involved in several process of cancer progression.…”

Section: Introductionmentioning

confidence: 99%